Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 13/20 | 0.41 |
| ▸ | THRB | P10828 | 13/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23168954 | 0.91 | THRA (0.42) | MEN1KMT2ATHRATHRBCYP2C8 | |
| SCHEMBL23168723 | 0.90 | THRA (0.50) | MEN1KMT2ATHRATHRBCYP2C8 | |
| SCHEMBL23168791 | 0.90 | THRB (0.43) | MEN1KMT2ATHRATHRBCYP2C8 | |
| SCHEMBL23168929 | 0.82 | THRA (0.49) | THRATHRBCYP2C8CYP2C9SMN1; SMN2 | |
| SCHEMBL29821635 | 0.82 | THRA (0.47) | MEN1KMT2ATHRATHRBCYP2C8 | |
| SCHEMBL23168655 | 0.82 | THRA (0.47) | MEN1KMT2ATHRATHRBCYP2C8 | |
| SCHEMBL23168930 | 0.82 | THRA (0.51) | MEN1KMT2ATHRATHRBCYP2C8 | |
| SCHEMBL23168776 | 0.82 | THRA (0.51) | THRATHRBCYP2C8CYP2C9SMN1; SMN2 | |
| SCHEMBL23168754 | 0.82 | THRA (0.49) | THRATHRBCYP2C8CYP2C9SMN1; SMN2 | |
| SCHEMBL29822030 | 0.81 | THRA (0.46) | THRATHRBCYP2C8CYP2C9MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| EP-4036090-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021057791-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | 广东东阳光药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | MEN1 891/4885KMT2A 2737/4885THRA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.